Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Three New Methods for Diagnosing Pancreas Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by University of Copenhagen.
Recruitment status was:  Recruiting
Information provided by:
University of Copenhagen Identifier:
First received: November 25, 2005
Last updated: February 25, 2009
Last verified: February 2009
The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.

Condition Intervention
Pancreas Cancer
Procedure: Ultrasound and contrast agent

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
Official Title: Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer

Resource links provided by NLM:

Further study details as provided by University of Copenhagen:

Estimated Enrollment: 80
Study Start Date: February 2005
Estimated Study Completion Date: January 2009
Intervention Details:
    Procedure: Ultrasound and contrast agent
    contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspicion of cancer of the pancreas
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00259532

Contact: Hanne S Grossjohann, MD +45 35453419

Copenhagen University Hospital Recruiting
Copenhagen, Denmark, 2100
Contact: Hanne S Grossjohann, MD    +45 35453419   
Principal Investigator: Hanne S Grossjohann, MD         
Sponsors and Collaborators
University of Copenhagen
Principal Investigator: Michael B Nielsen, DMSc Department of Radiology, Section of Ultrasound
  More Information Identifier: NCT00259532     History of Changes
Other Study ID Numbers: (KF) 01 268342
Study First Received: November 25, 2005
Last Updated: February 25, 2009

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gastrointestinal Agents processed this record on April 28, 2017